Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates
Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners
Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock
Genelux Corporation Announces Proposed Public Offering of Common Stock
Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer
Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates
Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates
Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development
Genelux Corporation (GNLX) Upgraded to Buy: Here's What You Should Know
Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates
Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Down -29.7% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround
Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock
Genelux Corporation Announces New Chief Financial Officer
Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright
Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference
Genelux: 2nd Half Of 2025 PRROC Data Is Major Inflection Point
Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer
Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit
Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference
Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates
Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2024
Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants
Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants
Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates
Down -48.37% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround
Down -45.44% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround
After Plunging -26.21% in 4 Weeks, Here's Why the Trend Might Reverse for Genelux Corporation (GNLX)
All You Need to Know About Genelux Corporation (GNLX) Rating Upgrade to Buy
Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer
Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates
Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference
Genelux: Biotech To Watch With Oncolytic Virus Immunotherapy In Late-Stage Testing
Genelux Corporation Announces New Chief Financial Officer
Genelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business Updates
Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2023
Why Shares of Genelux Climbed This Week
Genelux Corporation Strengthens Senior Management and Clinical Team with Promotions and New Hires
Genelux: A Game Changer In Platinum-Resistant Ovarian Cancer
Genelux Corporation Announces Publication of Phase I Trial Results of Intrapleural Administration of Olvi-Vec in Patients with Malignant Pleural Effusion from Mesothelioma, Lung or Breast Cancers in Frontiers in Immunology
IPO Round Up of First Half of 2023
Why Shares of Genelux Corporation Jumped This Week
Genelux: Recent IPO With Phase 3 Stage Oncolytic Virus Cancer Therapy
5 Best and Worst Performing Small-Cap Stocks in February 2023
Hot Stocks And Hot Wings Serve Up Spicy Breakouts And Buy Zones
Genelux IPO prices at bottom of range